Alcon is leading in eye care innovation.
We have a long history of industry firsts.
Thanks to our deep research capabilities and global commercial footprint, we are a trusted partner to many innovative companies.
We have completed approximately 30 development/licensing transactions since 2016.
In 2019, we invested $584 million in research and development, representing 7.9% of our net sales to third parties.
Also in 2019, we received 21 significant product approvals, launched 22 key products, and had 14 first inmarket launches. We have more than 110 pipeline products under development and over 1,300 associates working in R&D.
Alcon is in a position of considerable strength and has a unique opportunity to grow in the large, attractive and expanding $25 billion global eye care device market (Surgical: $10 billion; Vision Care $15 billion).